Base de dados : MEDLINE
Pesquisa : E05.916.290 [Categoria DeCS]
Referências encontradas : 1355 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 136 ir para página                         

  1 / 1355 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346200
[Au] Autor:Wu G; Yeung S; Chen F
[Ad] Endereço:TESARO Inc., Waltham, Massachusetts. gwu@tesarobio.com.
[Ti] Título:Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride.
[So] Source:Int J Pharm Compd;21(1):76-82, 2017 Jan-Feb.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 RA, and dexamethasone combination therapy is standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein we describe the physical and chemical stability of rolapitant injectable emulsion 166.5 mg in 92.5 mL (185 mg hydrochloride salt) admixed with palonosetron injection 0.25 mg in 5 mL (0.28 mg hydrochloride salt). Admixtures were prepared and stored in two types of container closures (110-mL Crystal Zenith plastic and glass bottles) and four types of intravenous administration sets (or intravenous tubing sets). Assessment of the physical and chemical stability was conducted on the admixtures in the ready-to-use container closure systems as supplied by the manufacturer, stored at room temperature (20°C to 25°C under fluorescent light), and evaluated at 0, 1, and 6 hours; 1 and 2 days; and under refrigeration (2°C to 8°C protected from light) after 1, 3, and 7 days. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C initially, and then after 20 hours (total 27 hours) at 2°C to 8°C protected from light. Physical stability was assessed by visual examination of the container contents under normal room light, and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations and impurity levels with high-performance liquid chromatographic analysis. The results indicated that all samples were physically compatible throughout the duration of the study. The pH, turbidity, and particulate matter of the admixture stayed within narrow and acceptable ranges. Rolapitant admixed with palonosetron was chemically stable when admixed in glass and Crystal Zenith bottles for at least 48 hours at room temperature and for 7 days under refrigeration, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 hours at 2°C to 8°C. No loss of potency of any admixed components occurred in the samples stored at the two temperature ranges and time period studied.
[Mh] Termos MeSH primário: Antieméticos/química
Isoquinolinas/química
Antagonistas do Receptor de Neuroquinina-1/química
Quinuclidinas/química
Antagonistas da Serotonina/química
Compostos de Espiro/química
[Mh] Termos MeSH secundário: Antieméticos/administração & dosagem
Cromatografia Líquida de Alta Pressão
Combinação de Medicamentos
Incompatibilidade de Medicamentos
Embalagem de Medicamentos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Emulsões
Vidro/química
Seres Humanos
Concentração de Íons de Hidrogênio
Injeções Intravenosas
Isoquinolinas/administração & dosagem
Luz
Antagonistas do Receptor de Neuroquinina-1/administração & dosagem
Plásticos/química
Quinuclidinas/administração & dosagem
Antagonistas da Serotonina/administração & dosagem
Solubilidade
Compostos de Espiro/administração & dosagem
Temperatura Ambiente
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one); 0 (Antiemetics); 0 (Drug Combinations); 0 (Emulsions); 0 (Isoquinolines); 0 (Neurokinin-1 Receptor Antagonists); 0 (Plastics); 0 (Quinuclidines); 0 (Serotonin Antagonists); 0 (Spiro Compounds); 5D06587D6R (palonosetron)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  2 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28346199
[Au] Autor:Wu G; Yeung S; Chen F
[Ad] Endereço:TESARO Inc., Waltham, Massachusetts. gwu@tesarobio.com.
[Ti] Título:Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate.
[So] Source:Int J Pharm Compd;21(1):66-75, 2017 Jan-Feb.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone combination therapy is the standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein, we describe the physical and chemical stability of an injectable emulsion of the Neurokinin-1 receptor antagonist rolapitant 185 mg in 92.5 mL (free base, 166.5 mg in 92.5 mL) admixed with either 2.5 mL of dexamethasone sodium phosphate (10 mg) or 5 mL of dexamethasone sodium phosphate (20 mg). Admixtures were prepared and stored in two types of container closures (glass and Crystal Zenith plastic bottles) and four types of intravenous administration tubing sets (or intravenous tubing sets). The assessment of the physical and chemical stability was conducted on admixtures packaged in bottled samples stored at room temperature (20°C to 25°C under fluorescent light) and evaluated at 0, 1, and 6 hours. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C, and then after 20 hours (total 27 hours) under refrigeration (2°C to 8°C) and protected from light. Physical stability was assessed by visually examining the bottle contents under normal room light and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations through high-performance liquid chromatographic analysis. Results showed that all samples were physically compatible throughout the duration of the study. The admixtures stayed within narrow and acceptable ranges in pH, turbidity, and particulate matter. Admixtures of rolapitant and dexamethasone were chemically stable when stored in glass and Crystal Zenith bottles for at least 6 hours at room temperature, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 (total 27 hours) hours at 2°C to 8°C. No loss of potency of any admixed component occurred in the samples stored at the temperature ranges studied.
[Mh] Termos MeSH primário: Antieméticos/química
Dexametasona/análogos & derivados
Glucocorticoides/química
Antagonistas do Receptor de Neuroquinina-1/química
Compostos de Espiro/química
[Mh] Termos MeSH secundário: Antieméticos/administração & dosagem
Cromatografia Líquida de Alta Pressão
Dexametasona/administração & dosagem
Dexametasona/química
Combinação de Medicamentos
Composição de Medicamentos
Incompatibilidade de Medicamentos
Embalagem de Medicamentos
Estabilidade de Medicamentos
Armazenamento de Medicamentos
Emulsões
Vidro/química
Glucocorticoides/administração & dosagem
Concentração de Íons de Hidrogênio
Injeções Intravenosas
Luz
Antagonistas do Receptor de Neuroquinina-1/administração & dosagem
Plásticos/química
Compostos de Espiro/administração & dosagem
Temperatura Ambiente
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one); 0 (Antiemetics); 0 (Drug Combinations); 0 (Emulsions); 0 (Glucocorticoids); 0 (Neurokinin-1 Receptor Antagonists); 0 (Plastics); 0 (Spiro Compounds); 2BP70L44PR (dexamethasone 21-phosphate); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE


  3 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28131059
[Au] Autor:Pires FQ; Angelo T; Silva JK; Sá-Barreto LC; Lima EM; Gelfuso GM; Gratieri T; Cunha-Filho MS
[Ad] Endereço:Laboratory of Food, Drug and Cosmetics (LTMAC), School of Health Sciences, University of Brasília, Brasília, DF, Brazil.
[Ti] Título:Use of mixture design in drug-excipient compatibility determinations: Thymol nanoparticles case study.
[So] Source:J Pharm Biomed Anal;137:196-203, 2017 Apr 15.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The objective of this work was to access thymol-excipient compatibility using an alternative protocol of mixture design subsidizing the development of nanostructures lipid carriers containing this drug. Simultaneous DTA-TG analyses associated with infrared spectroscopy were performed according to simplex centroid mixture designs with three components. Two designs were used: the design A containing stearic acid (SA), soybean lecithin (LC), and sodium taurodeoxycholate (TAU) and the design B, where TAU was replaced by polysorbate 80 (P80). Assays allowed for a quantitative evaluation of thermal events involved with thymol (TML) - melting and evaporation -, as well as events related to excipients decomposition and overall system stability. Although the anionic surfactant TAU did not interact with TML in solid state, chemical and physical stability were compromised after drug melting. Alternatively, nonionic surfactant P80 could be a good excipient option, as TML formulation stability was not influenced by it. Fatty acid SA did not compromise TML stability alone, but, when in combination with other formulation components, negative interaction leading to a possible decomposition of the system was observed. Finally, phospholipid LC solubilizes TML extending its evaporation to higher temperatures; hence, drug stability may be increased. In conclusion, the use of mixture design in the evaluation of multicomponent systems is a valuable tool for identification of synergistic effects of excipients, providing more complete information on formulation development. In addition, the association of techniques employed allowed inferring with certainty if thermal interactions could compromise formulation stability.
[Mh] Termos MeSH primário: Excipientes/química
Nanopartículas/química
Nanoestruturas/química
Timol/química
[Mh] Termos MeSH secundário: Química Farmacêutica/métodos
Incompatibilidade de Medicamentos
Estabilidade de Medicamentos
Fosfolipídeos/química
Espectrofotometria Infravermelho/métodos
Tensoativos/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Phospholipids); 0 (Surface-Active Agents); 3J50XA376E (Thymol)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170608
[Lr] Data última revisão:
170608
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE


  4 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28397414
[Au] Autor:Dhiman N; Awasthi R; Jindal S; Khatri S; Dua K
[Ad] Endereço:Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Tehsil-Dehra, Distt-Kangra, Himachal Pradesh, India.
[Ti] Título:Development of Bilayer Tablets with Modified Release of Selected Incompatible Drugs.
[So] Source:Polim Med;46(1):5-15, 2016 Jan-Jun.
[Is] ISSN:0370-0747
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The oral route is considered to be the most convenient and commonly-employed route for drug delivery. When two incompatible drugs need to be administered at the same time and in a single formulation, bilayer tablets are the most appropriate dosage form to administer such incompatible drugs in a single dose. OBJECTIVES: The aim of the present investigation was to develop bilayered tablets of two incompatible drugs; telmisartan and simvastatin. MATERIAL AND METHODS: The bilayer tablets were prepared containing telmisartan in a conventional release layer using croscarmellose sodium as a super disintegrant and simvastatin in a slow-release layer using HPMC K15M, Carbopol 934P and PVP K 30 as matrix forming polymers. The tablets were evaluated for various physical properties, drug-excipient interactions using FTIR spectroscopy and in vitro drug release using 0.1M HCl (pH 1.2) for the first hour and phosphate buffer (pH 6.8) for the remaining period of time. The release kinetics of simvastatin from the slow release layer were evaluated using the zero order, first order, Higuchi equation and Peppas equation. RESULTS: All the physical parameters (such as hardness, thickness, disintegration, friability and layer separation tests) were found to be satisfactory. The FTIR studies indicated the absence of interactions between the components within the individual layers, suggesting drug-excipient compatibility in all the formulations. No drug release from the slow-release layer was observed during the first hour of the dissolution study in 0.1M HCl. The release-controlling polymers had a significant effect on the release of simvastatin from the slow-release layer. Thus, the formulated bilayer tablets avoided incompatibility issues and proved the conventional release of telmisartan (85% in 45 min) and slow release of simvastatin (80% in 8 h). CONCLUSIONS: Stable and compatible bilayer tablets containing telmisartan and simvastatin were developed with better patient compliance as an alternative to existing conventional dosage forms.
[Mh] Termos MeSH primário: Benzimidazóis/administração & dosagem
Benzoatos/administração & dosagem
Combinação de Medicamentos
Sinvastatina/administração & dosagem
Comprimidos/síntese química
[Mh] Termos MeSH secundário: Benzimidazóis/farmacocinética
Benzoatos/farmacocinética
Carboximetilcelulose Sódica
Incompatibilidade de Medicamentos
Liberação Controlada de Fármacos
Derivados da Hipromelose
Cinética
Sinvastatina/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Benzimidazoles); 0 (Benzoates); 0 (Drug Combinations); 0 (Tablets); 3NXW29V3WO (Hypromellose Derivatives); AGG2FN16EV (Simvastatin); K679OBS311 (Carboxymethylcellulose Sodium); U5SYW473RQ (telmisartan); Z78RG6M2N2 (hypromellose 2208 (15000 MPA.S))
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.17219/pim/62511


  5 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28333677
[Au] Autor:Foushee JA; Meredith P; Fox LM; Grace E
[Ad] Endereço:Presbyterian College School of Pharmacy, Clinton, South Carolina. jafoushee@presby.edu.
[Ti] Título:Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
[So] Source:Int J Pharm Compd;20(4):328-332, 2016 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Parenteral beta-blocker therapy via continuous infusion has shown promising results for improved outcomes for patients with septic shock. As patients with septic shock may require multiple intravenous medications, compatibility is necessary to co-infuse these medications through a y-site connector. The purpose of this study was to examine the physical compatibility of select intravenous drugs used for patients with septic shock combined with various intravenous beta-blockers including esmolol, labetalol, and metoprolol through a simulated y-site infusion. The tested drugs included albumin, levothyroxine, acetaminophen, esomeprazole, doripenem, epinephrine, ibuprofen, norepinephrine, levofloxacin, cefepime, ciprofloxacin, meropenem, cisatracurium, and hydrocortisone. Equal volumes of normal saline, esmolol, labetalol, and metoprolol were combined with each test drug at maximum or commercially available concentrations as appropriate used clinically in intensive care units.The samples were examined visually against a white and black background andalso using turbidimetric measurements to determine physical compatibility.Beginning immediately after mixing, observations and analyses were taken over a one-hour period at 15-minute intervals. Each test was performed in triplicate. Many of the test drugs demonstrated visual and/or turbidimetric physical compatibility when combined with esmolol, labetalol, or metoprolol during a simulated y-site infusion. Albumin, cefepime, and hydrocortisone demonstrated physical incompatibility when combined with labetalol and should not be co-infused with labetalol. Esomeprazole and ibuprofen demonstrated physical incompatibility when combined with esmolol and labetalol and should not be co-infused with either beta-blocker. Esmolol and ciprofloxacin mixtures exhibited a statistically significant difference from control solutions and should not be co-infused.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos beta/administração & dosagem
Antagonistas Adrenérgicos beta/química
Sistemas de Liberação de Medicamentos/instrumentação
Unidades de Terapia Intensiva
Serviço de Farmácia Hospitalar
Polimedicação
Choque Séptico/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/efeitos adversos
Composição de Medicamentos
Incompatibilidade de Medicamentos
Estabilidade de Medicamentos
Desenho de Equipamento
Seres Humanos
Infusões Intravenosas
Nefelometria e Turbidimetria
Medição de Risco
Choque Séptico/diagnóstico
Solubilidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170605
[Lr] Data última revisão:
170605
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE


  6 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27576669
[Au] Autor:Shi C; Sun Y; Wu H; Zhu C; Wei G; Li J; Chan T; Ouyang D; Mao S
[Ad] Endereço:School of Pharmacy, Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China.
[Ti] Título:Exploring the effect of hydrophilic and hydrophobic structure of grafted polymeric micelles on drug loading.
[So] Source:Int J Pharm;512(1):282-291, 2016 Oct 15.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The objective of this paper is to explore the effect of hydrophilic and hydrophobic structure of grafted polymeric micelles on drug loading, and elucidate whether drug-polymer compatibility, as predicted by Hansen solubility parameters (HSPs), can be used as a tool for drug-polymer pairs screening and guide the design of grafted polymeric micelles. HSPs of 27 drugs and three grafted copolymers were calculated according to group contribution method. The drug-polymer compatibilities were evaluated using the approaches of Flory-Huggins interaction parameters (χFH) and polarity difference (â–³Xp). Two models, model A and B, were put forward for drug-polymer compatibility prediction. In model A, hydrophilic/hydrophobic part as a whole was regarded as one segment. And, in model B, hydrophilic and hydrophobic segments were evaluated individually. First of all, using chitosan (CS)-grafted-glyceryl monooeate (GMO) based micelle as an example, the suitability of model A and model B for predicating drug-polymer compatibility was evaluated theoretically. Thereafter, corresponding experiments were carried out to check the validity of the theoretical prediction. It was demonstrated that Model B, which evaluates drug compatibility with both hydrophilic and hydrophobic segments of the copolymer, is more reliable for drug-polymer compatibility prediction. Moreover, the approach of model B allows for the selection of a defined grafted polymer with for a specific drug and vice versa. Thus, drug compatibility evaluation via HSPs with both hydrophilic and hydrophobic segments is a suitable tool for the rational design of grafted polymeric micelles. The molecular dynamics (MD) simulation study provided further support to the established model and experimental results.
[Mh] Termos MeSH primário: Interações Hidrofóbicas e Hidrofílicas
Micelas
Preparações Farmacêuticas/química
Polímeros/química
[Mh] Termos MeSH secundário: Quitosana/química
Incompatibilidade de Medicamentos
Glicerídeos/química
Modelos Teóricos
Simulação de Dinâmica Molecular
Tamanho da Partícula
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glycerides); 0 (Micelles); 0 (Pharmaceutical Preparations); 0 (Polymers); 9012-76-4 (Chitosan); C4YAD5F5G6 (monoolein)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160901
[St] Status:MEDLINE


  7 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27552677
[Au] Autor:Ocaña-Zurita MC; Juárez-Rojop IE; Genis A; Tovilla-Zárate CA; González-Castro TB; Lilia López-Narváez M; de la O de la O ME; Nicolini H
[Ad] Endereço:a División Académica de Ciencias de la Salud , Universidad Juárez Autónoma de Tabasco , Villahermosa , Tabasco , México ;
[Ti] Título:Potential drug-drug interaction in Mexican patients with schizophrenia.
[So] Source:Int J Psychiatry Clin Pract;20(4):249-53, 2016 Nov.
[Is] ISSN:1471-1788
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The aim of this study was to observe potential drug-drug interactions in the medication of Mexican schizophrenic patients. METHODS: We performed a retrospective and cross-sectional study that was carried out in a psychiatric clinic. Only the prescriptions of patients with schizophrenia whose diagnoses were based on the DSM-IV instrument were included in this study. The Drug Interactions Checker software ( http://www.drugs.com/drug_interactions.html ) was used in this study to analyse potential drug-drug interactions. RESULTS: In total, 86 of 126 patients were at risk of potential drug-drug interactions. Haloperidol and biperiden was the most common drug pair of 232 pairs evaluated. In our study, 13.8% of drug-drug interaction showed a major level of severity, whereas in 83.2%, the interaction was moderate. Finally, central nervous system (CNS) depression and anticholinergic effect were the main possible effects of drug-drug interaction. CONCLUSIONS: Our results revealed a high number of patients with schizophrenia receiving two or more drugs. The potential drug-drug interactions observed in the Mexican population are consistent with the concomitant use of antipsychotics, benzodiazepines, and antidepressants prescribed in schizophrenia that could cause central nervous system (CNS) depression and anticholinergic effect. Drug-drug interaction must be considered when the patient with schizophrenia is medicated.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Incompatibilidade de Medicamentos
Interações Medicamentosas
Antagonistas Muscarínicos/uso terapêutico
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Antipsicóticos/efeitos adversos
Biperideno/efeitos adversos
Biperideno/uso terapêutico
Estudos Transversais
Feminino
Haloperidol/efeitos adversos
Haloperidol/uso terapêutico
Seres Humanos
Masculino
México/epidemiologia
Meia-Idade
Antagonistas Muscarínicos/efeitos adversos
Estudos Retrospectivos
Esquizofrenia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Muscarinic Antagonists); 0FRP6G56LD (Biperiden); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170404
[Lr] Data última revisão:
170404
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160824
[St] Status:MEDLINE
[do] DOI:10.1080/13651501.2016.1213854


  8 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27476292
[Au] Autor:Maswadeh HM
[Ti] Título:DISSOLUTION AND COMPATIBILITY STUDY OF BINARY AND TERNARY INTERACTIVE MIXTURES OF INDOMETHACIN: COMPARISON WITH COMMERCIALLY AVAILABLE CAPSULES.
[So] Source:Acta Pol Pharm;73(3):739-48, 2016 May-Jun.
[Is] ISSN:0001-6837
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:The main objective of this work was to use Weibull distribution function and Baker-Lonsdale models to study the dissolution kinetics of prepared binary and ternary interactive mixtures containing indomethacin in comparison with three commercially available capsules of indomethacin, namely, Rothacin®, Indomin® and Indylon®. Differential scanning calorimetry (DSC) in conjunction with cloud point method was used to study the compatibility of indomethacin with polyvinylpyrrolidone (PVP) and lactose and to provide an explanation(s) for the insignificant increase in dissolution rate observed in the ternary interactive mixture as well as for the reduction in the dissolution rate observed from the binary system in our previous study. Results showed that the Weibull distribution function equation was the best fit to the dissolution data for all formulations used in this study. DSC curves showed that the decrease in dissolution rate from the binary and ternary interactive mixtures was due to incompatibility of indomethacin with PVP. Also DSC curves showed that lactose was compatible with indomethacin and that lactose was used as excipient in two commercial products (Rothacin® and Indylon®). Results from the cloud point method showed that the addition of indomethacin to 1% PVP solution containing ammonium sulfate (with cloud point at 76°C) reduces the cloud point of PVP indicating that there is an interaction between indomethacin and PVP, while the cloud point of 1% PVP containing ammonium sulfate was not affected by the addition of lactose.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/análise
Anti-Inflamatórios não Esteroides/química
Indometacina/análise
Indometacina/química
[Mh] Termos MeSH secundário: Varredura Diferencial de Calorimetria
Cápsulas
Incompatibilidade de Medicamentos
Excipientes
Lactose
Povidona
Solubilidade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Capsules); 0 (Excipients); FZ989GH94E (Povidone); J2B2A4N98G (Lactose); XXE1CET956 (Indomethacin)
[Em] Mês de entrada:1609
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160802
[St] Status:MEDLINE


  9 / 1355 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo SciELO Brasil
[PMID]:27462891
[Au] Autor:Leal KD; Leopoldino RW; Martins RR; Veríssimo LM
[Ad] Endereço:Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil.
[Ti] Título:Potential intravenous drug incompatibilities in a pediatric unit.
[So] Source:Einstein (Sao Paulo);14(2):185-9, 2016 Apr-Jun.
[Is] ISSN:2317-6385
[Cp] País de publicação:Brazil
[La] Idioma:eng; por
[Ab] Resumo:OBJECTIVE: To investigate potential intravenous drug incompatibilities and related risk factors in a pediatric unit. METHODS: A cross-sectional analytical study conducted in the pediatric unit of a university hospital in Brazil. Data on prescriptions given to children aged 0-15 years from June to October 2014 were collected. Prescriptions that did not include intravenous drugs and prescriptions with incomplete dosage regimen or written in poor handwriting were excluded. Associations between variables and the risk of potential incompatibility were investigated using the Student's t test and ANOVA; the level of significance was set at 5% (p<0.05). Relative risks were calculated for each drug involved in potential incompatibility with 95% confidence interval. RESULTS: A total of 222 children participated in the study; 132 (59.5%) children were male and 118 (53.2%) were aged between 0 and 2 years. The mean length of stay was 7.7±2.3 days. Dipyrone, penicillin G and ceftriaxona were the most commonly prescribed drugs. At least one potential incompatibility was detected in about 85% of children (1.2 incompatibility/patient ratio). Most incompatibilities detected fell into the non-tested (93.4%), precipitation (5.5%), turbidity (0.7%) or chemical decomposition (0.4%) categories. The number of drugs and prescription of diazepam, phenytoin, phenobarbital or metronidazole were risk factors for potential incompatibility. CONCLUSION: Most pediatric prescriptions involved potential incompatibilities, with higher prevalence of non-tested incompatibilities. The number of drugs and prescription of diazepam, phenobarbital, phenytoin or metronidazole were risk factors for potential incompatibilities. OBJETIVO: Avaliar o potencial de incompatibilidade dos medicamentos intravenosos, identificando possíveis fatores de risco em uma unidade pediátrica. MÉTODOS: Trata-se de um estudo observacional analítico do tipo transversal realizado na unidade de pediatria de um hospital de ensino no Brasil. Os dados foram coletados de junho a outubro de 2014 a partir da análise das prescrições de crianças (0 a 15 anos) hospitalizadas. Foram excluídas prescrições sem medicamento intravenoso e com posologia incompletas ou grafia inadequada. A associação entre as variáveis e o risco de potenciais incompatibilidades foi determinada pelo teste t de Student e ANOVA, considerando significativo para p<0,05. Calculou-se o risco relativo com intervalo de confiança de 95% de cada medicamento envolvido. RESULTADOS: Duzentos e vinte e duas crianças participaram do estudo, 132 (59,5%) eram do gênero masculino, 118 (53,2%) tinham idade entre 0 a 2 anos e estiveram internados em média 7,7±2,3 dias. Os medicamentos mais prescritos foram dipirona, penicilina G e ceftriaxona. Quase 85% das crianças apresentaram ao menos uma potencial incompatibilidade, razão de 1,2 incompatibilidades/paciente. Os tipos de incompatibilidades mais comuns foram: não testada (93,4%), precipitação (5,5%), turbidez (0,7%) e decomposição química (0,4%). Os fatores associados a potenciais incompatibilidades foram: número de medicamentos e a prescrição dos medicamentos diazepam, fenitoína, fenobarbital e metronidazol. CONCLUSÃO: A maioria das prescrições pediátricas apresentou potenciais incompatibilidades e a incompatibilidade não testada foi o tipo mais comum. O número de medicamentos e a prescrição dos medicamentos diazepam, fenobarbital, fenitoína e metronidazol foram fatores de risco para potenciais incompatibilidades.
[Mh] Termos MeSH primário: Administração Intravenosa/efeitos adversos
Incompatibilidade de Medicamentos
Hospitais Universitários/estatística & dados numéricos
Pediatria/estatística & dados numéricos
[Mh] Termos MeSH secundário: Administração Intravenosa/estatística & dados numéricos
Adolescente
Brasil
Criança
Pré-Escolar
Estudos Transversais
Feminino
Seres Humanos
Lactente
Recém-Nascido
Masculino
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170308
[Lr] Data última revisão:
170308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160728
[St] Status:MEDLINE


  10 / 1355 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27448404
[Au] Autor:Fusi-Schmidhauser T; Caronzolo D; Gamondi C
[Ad] Endereço:Palliative Care Department, Institute of Oncology of Southern Switzerland, Bellinzona, Switzerland. tanja.fusi-schmidhauser@eoc.ch.
[Ti] Título:Multidrug infusions in a Swiss palliative care unit: assessment of frequent combinations in terms of clinical effectiveness, compatibility, and stability.
[So] Source:Support Care Cancer;24(12):4971-4978, 2016 Dec.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The objectives of this study were to trace, monitor, and assess for clinical effectiveness, visual compatibility, and stability of commonly used combinations of drugs for patients hospitalized in a Swiss palliative care unit, over a 12-month period. METHODS: In this longitudinal analysis, commonly used multidrug combinations were monitored with a duly created data collection sheet for healthcare professionals. Assessment of visual changes of the mixtures and the evaluation of major changes in the overall symptom control over time were recorded. The clinical changes were classified according to reasonable correlation to the modality of drug administration and not to clinical evolution of the underlying disease. RESULTS: Over a 12-month period, a total of 48 multidrug infusions were recorded and monitored. The infusions were composed of two, three, four, or five active principles. Infusions were given over a 24-h period, mainly intravenously, either through an implantable venous access port or a peripheral venous access. Main diluent was normal saline solution. Commonly used drug combinations included morphine and haloperidol, morphine, haloperidol and octreotide, morphine, haloperidol, octreotide, and chlorpromazine. No precipitations were observed during the study. Patients maintained a clinical stability and no salient changes in symptom control were attributed to inefficacy of the multidrug infusions. CONCLUSIONS: The use of multidrug infusions for parenteral administration appears to confirm an adequate visual compatibility and stability, while maintaining effectiveness in terms of overall symptom control.
[Mh] Termos MeSH primário: Incompatibilidade de Medicamentos
Infusões Intravenosas/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Combinação de Medicamentos
Estabilidade de Medicamentos
Feminino
Haloperidol/administração & dosagem
Seres Humanos
Estudos Longitudinais
Meia-Idade
Morfina/administração & dosagem
Cuidados Paliativos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 76I7G6D29C (Morphine); J6292F8L3D (Haloperidol)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160725
[St] Status:MEDLINE



página 1 de 136 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde